Bio-Works Technologies AB - Business Update first quarter 2026

Net sales in Q1 2026 were 29.3 MSEK versus 9.0 MSEK in the comparator period (≈+226%), with last two quarters at 53.0 MSEK (11.6 MSEK comparator) and last four quarters 82.8 MSEK (28.5 MSEK comparator). Order intake for Q1 was 15.5 MSEK, down roughly 51% from 31.6 MSEK, and the order book stood at 17.7 MSEK, indicating weaker incoming demand despite higher reported sales.

Analysis

The pattern points to demand erosion concentrated in order-driven capital goods markets rather than a one-off revenue accounting glitch; that typically cascades into working-capital stress for tier-2/3 suppliers within 1–3 quarters as receivables lengthen and inventory gets marked down. That puts balance-sheet-rich OEMs in the buying seat — not only via M&A but via price discipline on components, which can compress small suppliers’ margins even if end-market volumes stabilize.

Second-order supply-chain effects: prolonged order weakness forces OEMs to delay capacity expansion and spare-parts replenishment, which disproportionately hurts firms with high fixed-cost footprints and low recurring-service revenue, while boosting the relative value of installed-base service providers and digital-analytics aftermarket streams. Currency and public-procurement dynamics create short-window reversals — a single stimulus-driven bid from a major buyer or a large public contract can reflate order books inside 2–6 months and produce outsized EPS upside for lean, execution-capable players.

Key risks and catalysts to monitor are creditor stress at small suppliers (tail risk: bankruptcy-triggered production interruptions within 3–9 months), PMI and capex surveys (near-term demand signal within weeks), and backlog conversion rates reported in the next two quarterly cycles. The consensus risk is treating this as a linear slowdown; the contrarian pay-off is that earnings recoveries in this space are often lumpy and front-loaded — a visible pick-up in order intake can drive 20–40% equity re-ratings for the right names within 6–12 months.

Key Decisions for Investors

• Long ATCO-B.ST (Atlas Copco B) — 9–12 month call-spread (buy 12-month ATM call, sell 12-month call ~30% OTM) to pay for premium. Thesis: strong installed-base service and balance sheet enable upside if orders reflate; target +25–35% equity return if order pickup occurs; max loss = net premium (~100% of premium).
• Long SKF-B.ST (SKF B) — buy equity and hedge with 6–9 month puts ~10% OTM to limit downside. Thesis: high aftermarket exposure cushions revenues and accelerates cash conversion on any modest end-market stabilization; expected 2:1 upside/downside if order-book stabilizes within two quarters.
• Pair trade: Long ABB (ABB) vs Short SAND.ST (Sandvik) — 6–12 month horizon, equal notional. Rationale: favor automation/service-led industrials (ABB) with recurring revenue over mining/capital-cycle exposed peers (Sandvik) if order weakness persists; set stop-loss at 8% on the pair. Expected asymmetric payoff: 20% upside on ABB capture vs 10–12% downside protective buffer on Sandvik short if macro improves unexpectedly.
• Event hedge: Buy protection on a small-cap Swedish industrial basket (buy 6–12 month puts or use protective put spreads) to guard against supplier insolvency cascade. Cost is insurance for a low-probability tail; if a key supplier fails, expect idiosyncratic winners among large OEMs and 15–30% drops in vulnerable small caps.